Nab-Sirolimus + Endocrine Therapy for Ovarian Cancer

Overseen By Lead Nurse

Age: 18+

Sex: Female

Trial Phase: Phase 2

Sponsor: University of Oklahoma

Must not be taking: Steroids, Immunosuppressants, CYP3A4 drugs

Disqualifiers: Infections, Lung disease, Cardiac disease, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 1

Duration: 21-day cycles, ongoing as long as effective

37 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a combination of two treatments: nab-sirolimus (an experimental treatment) and fulvestrant (also known as Faslodex, an endocrine therapy), for individuals with recurrent low-grade serous ovarian cancer. The main goal is to evaluate the effectiveness and safety of these treatments when used together. This trial may suit those diagnosed with this specific type of ovarian cancer who have experienced a recurrence. Participants should have measurable disease and should not have previously received treatments like nab-sirolimus or similar drugs. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of people.

Will I have to stop taking my current medications?

The trial requires that you stop taking certain medications, specifically those that are strong inducers or substrates of CYP3A4, at least 5 half-lives before starting the trial. If you are taking any of these medications, you will need approval from the Medical Monitor to participate.

Is there any evidence suggesting that nab-sirolimus + endocrine therapy is likely to be safe for humans?

Research has shown that the combination of nab-sirolimus and Fulvestrant has been studied for safety and effectiveness. Nab-sirolimus is a new version of sirolimus, designed to better target tumors. In earlier studies, patients received this treatment on a set schedule, and most tolerated it well. While side effects can occur, these studies did not find any unexpected or severe issues.

Fulvestrant, the other part of the combination, is already approved for treating certain types of breast cancer. It is usually well-tolerated, though some patients might experience mild to moderate side effects, such as tiredness or nausea.

This trial is in Phase 2, indicating that the treatment has already demonstrated some safety in earlier trials. This phase focuses more on the treatment's effectiveness and examines safety in a larger group of people. ^{1 2 3 4 5}

Why are researchers excited about this study treatment for ovarian cancer?

Researchers are excited about the combination of nab-sirolimus and fulvestrant for ovarian cancer because it represents a novel approach compared to current treatments. Unlike standard therapies that often focus on chemotherapy and hormone blockers, this combination leverages nab-sirolimus, which is a nanoparticle form of an mTOR inhibitor, to target cancer cell growth in a new way. Additionally, by pairing nab-sirolimus with fulvestrant, a well-established estrogen receptor degrader, the treatment aims to not only inhibit tumor growth but also disrupt hormone-driven cancer progression. This dual-action strategy holds promise for more effective management of ovarian cancer.

What evidence suggests that nab-sirolimus + endocrine therapy might be an effective treatment for ovarian cancer?

Research has shown that nab-sirolimus yields promising results in treating certain tumors, achieving an 89% success rate in shrinking tumors with specific genetic changes. This trial will test nab-sirolimus combined with fulvestrant, which blocks estrogen and has effectively treated recurring breast cancer. Fulvestrant may also combat ovarian cancer by cutting off the tumor's estrogen supply. Together, these treatments in this trial aim to stop cancer cells from growing and spreading. ^{6 7 8 9 10}

Who Is on the Research Team?

Christina Washington, MD

Principal Investigator

OU Health Stephenson Cancer Center

Are You a Good Fit for This Trial?

This trial is for adults with recurrent low-grade serous ovarian cancer. Participants must be in good physical condition (ECOG 0-1), have measurable disease, and adequate organ function. They should not have had major surgery or radiation within the last 4 weeks and 2 weeks respectively, and must agree to effective contraception if of childbearing potential.

Inclusion Criteria

My ovarian cancer is low-grade and has come back.

I am fully active and can carry on all my pre-disease activities without restriction.

It has been over 2 weeks since my last radiation therapy session.

Exclusion Criteria

I have not taken drugs targeting the mTOR pathway, except possibly one chemotherapy or a MEK inhibitor.

I have severe lung issues and need oxygen sometimes.

I have not had a stroke or mini-stroke in the last 6 months.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive nab-sirolimus on days 1 and 8 and fulvestrant on days 1 and 15 of cycle 1, then every 21-day cycle

21-day cycles, ongoing as long as effective

Visits on days 1, 8, and 15 of cycle 1, then every 21 days

Follow-up

Participants are monitored for safety and effectiveness after treatment completion

Up to 2 years

Long-term monitoring

Participants are monitored for disease progression and adverse events

Up to 3 years

What Are the Treatments Tested in This Trial?

Interventions

• Fulvestrant
• nab-Sirolimus

Trial Overview The study is testing the combination of nab-Sirolimus, a targeted therapy drug, with Fulvestrant, an endocrine therapy. It aims to assess how safe and effective this combo is for patients who've seen their ovarian cancer return after previous treatments.

How Is the Trial Designed?

Group I: nab-sirolimus + Fulvestrant Experimental Treatment 2 Interventions

Patients will be treated with the combination nab-sirolimus (100 mg/m2 intravenous injection on day 1 and 8 of each 21-day cycle) and fulvestrant (500mg intramuscular injection on days 1 and 15 of cycle 1 and then every 21 days).

Fulvestrant is already approved in European Union, United States, Canada, Japan for the following indications:

Approved in European Union as Faslodex for:

• Hormone receptor-positive metastatic breast cancer
• Locally advanced breast cancer

Approved in United States as Faslodex for:

• Hormone receptor-positive metastatic breast cancer
• Locally advanced breast cancer

Approved in Canada as Faslodex for:

• Hormone receptor-positive metastatic breast cancer
• Locally advanced breast cancer

Approved in Japan as Faslodex for:

• Hormone receptor-positive metastatic breast cancer
• Locally advanced breast cancer

Who Is Running the Clinical Trial?

University of Oklahoma

Lead Sponsor

Trials

484

Recruited

95,900+

Aadi Bioscience, Inc.

Industry Sponsor

Trials

18

Recruited

580+

Published Research Related to This Trial

In a study involving 44 women with platinum-refractory ovarian cancer or advanced endometrial carcinoma, the mTOR inhibitor temsirolimus was found to be well tolerated with mild toxicity, but it did not meet the predefined efficacy criteria for progression-free survival.

Despite the overall lack of efficacy, some patients experienced long-lasting disease stabilization, indicating that temsirolimus may still have potential benefits for a subset of patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8). Emons, G., Kurzeder, C., Schmalfeldt, B., et al.[2016]

In a phase 1b study involving 23 patients with advanced solid tumors, sirolimus at a weekly dose of 40 mg combined with nab-paclitaxel showed an acceptable safety profile, with manageable dose-limiting toxicities.

The study found that changes in AKT expression and FDG activity after treatment could serve as early predictors of response to sirolimus, indicating potential biomarkers for treatment efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors. Abu-Khalaf, MM., Baumgart, MA., Gettinger, SN., et al.[2021]

Sirolimus is an immunosuppressive drug that, while having a range of organ and tissue toxicities, offers significant benefits for renal transplant recipients, such as reducing the need for calcineurin inhibitors like cyclosporine and tacrolimus.

It also lowers the risk of certain post-transplant cancers, including lymphomas and Kaposi sarcomas, and has less nephrotoxicity compared to traditional calcineurin inhibitors, making it a valuable option in managing transplant patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Current approaches to the use of sirolimus in renal transplantation. Kahan, BD.[2014]

In a study of 47 patients with recurrent ovarian, peritoneal, or fallopian tube cancer, nab-paclitaxel demonstrated a significant objective response rate of 64%, indicating its efficacy in this patient population.

The treatment was associated with manageable toxicities, primarily neutropenia (24%) and neuropathy (9%), suggesting that nab-paclitaxel could be a viable option for patients with limited therapeutic choices.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. Teneriello, MG., Tseng, PC., Crozier, M., et al.[2015]

A phase 3 study (J-AXEL) is underway to compare the efficacy and safety of nab-paclitaxel to docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC), involving randomization of patients to receive either treatment until disease progression or unacceptable toxicity.

The primary goal of the study is to demonstrate that nab-paclitaxel is noninferior to docetaxel in terms of overall survival, which could establish nab-paclitaxel as a new treatment option for these patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. Yoneshima, Y., Morita, S., Ando, M., et al.[2018]

In a study of 24 renal transplant recipients who switched from tacrolimus to sirolimus, there was a significant increase in regulatory T cell frequencies and improved renal function after 3 and 6 months, suggesting enhanced immune regulation.

Conversion to sirolimus also led to decreased levels of inflammatory cytokines and changes in STAT protein activation, indicating a potential for reduced toxicity and promotion of immune tolerance in transplant patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Differential regulation of Tregs and Th17/Th1 cells by a sirolimus-based regimen might be dependent on STAT-signaling in renal transplant recipients. Li, Y., Shi, Y., Liao, Y., et al.[2015]

Sirolimus, an mTOR inhibitor, when conjugated to albumin nanoparticles and combined with paclitaxel, significantly reduced cell viability in breast cancer cell lines, indicating enhanced anticancer effects compared to non-conjugated nanoparticles.

The study found that sirolimus-conjugated nanoparticles with lower concentrations of paclitaxel (0.01 μg/mL) resulted in a 44% cell viability in MDA-MB-468 cells, compared to 53% for non-conjugated nanoparticles, suggesting that the timing and method of drug release can optimize treatment efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Enhanced Cytotoxicity to Cancer Cells by Codelivery and Controlled Release of Paclitaxel-loaded Sirolimus-conjugated Albumin Nanoparticles. Behrouz, H., Esfandyari-Manesh, M., Khoeeniha, MK., et al.[2021]

Sirolimus, an mTOR inhibitor, effectively reduced the expression of HIF-1alpha protein and decreased tumor growth in an ovarian carcinoma model using athymic mice, indicating its potential as a therapeutic agent.

The combination of sirolimus with paclitaxel showed the most significant reduction in tumor burden (51.0%) and increased apoptosis in cancer cells, suggesting that sirolimus enhances the effectiveness of standard chemotherapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Inhibition of hypoxia-inducible factor 1alpha expression and tumor growth in SKOV3 ovarian cancer model by sirolimus]. Jiang, HY., Feng, YJ.[2015]

Sirolimus has become a foundational therapy for immunosuppression in transplant patients, significantly reducing the risk of acute allograft rejection by allowing over 80% reduction in calcineurin inhibitor exposure, which leads to better long-term renal function despite some increased risks of lymphoceles and impaired wound healing.

The drug also has anti-cancer properties by inhibiting mTOR, reducing tumor incidence in patients, and is relatively non-nephrotoxic, allowing for the withdrawal of steroid therapy and lower rates of viral infections, making it a promising option in immunosuppressive regimens.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine. Kahan, BD.[2014]

In a phase II study of 85 patients with metastatic breast cancer, the combination of nab-paclitaxel and gemcitabine showed a significant objective response rate of 52.4%, with a median progression-free survival of 7.9 months and overall survival of 25.8 months.

The treatment was generally well tolerated, with common side effects including neutropenia and peripheral neuropathy, and tumor/stromal Caveolin-1 levels were identified as potential predictive biomarkers for treatment efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial. Zhao, Y., Lv, F., Chen, S., et al.[2022]

Nab-paclitaxel, a nanoparticle albumin-bound form of paclitaxel, is the first nanotechnology-based drug approved for cancer treatment, showing significant promise in breast and pancreatic cancers.

This innovative drug not only enhances the effectiveness and reduces the toxicity of traditional treatments but also demonstrates activity in cancers that typically do not respond to standard taxane therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? Cucinotto, I., Fiorillo, L., Gualtieri, S., et al.[2022]

New targeted therapies for epithelial ovarian cancer are being developed, focusing on overcoming drug resistance and targeting specific receptors like HER, with combinations of drugs like erlotinib and cetuximab showing feasibility and good tolerance alongside standard chemotherapy.

Emerging treatments include proteasome inhibitors, mTOR inhibitors, and angiogenesis inhibitors, with ongoing trials exploring their effectiveness, indicating a shift towards personalized medicine based on genetic and molecular profiles of tumors.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic. Gadducci, A., Cosio, S., Genazzani, AR.[2019]

Tyrosine kinase inhibitors (TKIs) combined with chemotherapy show promise in improving progression-free survival (PFS) in ovarian cancer patients, based on emerging data from phase I and II trials.

mTOR inhibitors appear to be less effective in treating ovarian cancer, highlighting the need for further research into targeting multiple signaling pathways and advancing promising treatments to phase III trials.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Kinase Inhibitors and Ovarian Cancer. Katopodis, P., Chudasama, D., Wander, G., et al.[2023]

Citations

1. pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov/19239974/

A Phase II Study of Fulvestrant in the Treatment of Multiply- ... Fulvestrant, a novel estrogen receptor (ER) antagonist, has proven clinically beneficial and well-tolerated in treating recurrent breast cancer.

2. sciencedirect.com sciencedirect.com/science/article/abs/pii/S009082580900016X

A phase II study of fulvestrant in the treatment of multiply- ... Fulvestrant, delivered using the loading dose strategy, is well tolerated and appears to provide some benefit even in the setting of multiply recurrent disease.

3. nature.com nature.com/articles/s41598-021-83622-1

Real-world data of fulvestrant as first-line treatment ... Effectiveness outcomes. With a median follow-up period of 31.4 months, the median PFS with fulvestrant was 14.6 months (95% CI 10.9–19.9 months; ...

4. clinicaltrials.gov clinicaltrials.gov/study/NCT00617188

Fulvestrant in Treating Patients With Recurrent Ovarian ... Hormone therapy using fulvestrant may fight ovarian cancer by blocking the use of estrogen by the tumor cells.

5. international-journal-of-gynecological-cancer.com international-journal-of-gynecological-cancer.com/article/S1048-891X(24)00005-7/fulltext

An open-label, single-arm, prospective, multi-center, ... This study demonstrated that fulvestrant has a disease control rate of 100% in the treatment of patients with recurrent uterine sarcomas, sex cord-stromal ...

6. aadibio.com aadibio.com/aadi-bioscience-recieves-fda-orphan-product-development-grant-for-treatment-of-advanced-pecoma-2-2-2-2/

Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI ... Exploratory mutational analysis shows an 89% confirmed response rate in TSC2 mutated tumors; US FDA New Drug Application expected to be ...

7. withpower.com withpower.com/trial/phase-2-carcinoma-ovarian-epithelial-7-2024-b718a

Nab-Sirolimus + Endocrine Therapy for Ovarian Cancer This single arm phase II study proposes to evaluate the efficacy and safety of nab-sirolimus + endocrine therapy (Fulvestrant) in patients with recurrent low ...

8. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC11533328/

A Phase 1 Study of ABI‐009 (Nab‐sirolimus) in Combination ... Nab‐sirolimus was developed using albumin nanoparticle technology [8]. This enhances the accumulation of albumin‐bound drug in solid tumors, and ...

9. fda.gov fda.gov/drugs/resources-information-approved-drugs/fda-approves-sirolimus-protein-bound-particles-malignant-perivascular-epithelioid-cell-tumor

FDA approves sirolimus protein-bound particles for ... Patients received sirolimus protein-bound particles at 100 mg/m2 on days 1 and 8 of each 21-day cycle until disease progression or unacceptable ...

10. cdn.clinicaltrials.gov cdn.clinicaltrials.gov/large-docs/30/NCT03670030/Prot_SAP_002.pdf

A pilot phase 2 study of albumin-bound sirolimus ... The novel nanoparticle albumin-bound sirolimus (formerly nab-rapamycin, ABI-009) is freely dispersible in saline and is suitable for IV administration, and has ...